501 W. 1ST Ave.
Columbus, OH 43215 USA
ABITEC Corporation is dedicated to the advancement of essential bioavailability enhancement and formulation development technology. ABITEC develops and manufactures lipid-based excipients to enhance the bioavailability of poorly water-soluble and poorly permeable Active Pharmaceutical Ingredients (APIs) for the pharmaceutical industry. And now with the addition of Larodan, ABITEC has expanded its offerings to include high-purity research grade lipids.
ABITEC has an expansive portfolio of CAPMUL® bioavailability enhancers, which are medium-chain mono- and di-glycerides and propylene glycol esters. These functional lipid excipients act as solubilizers and emulsifiers in oral, topical, transdermal, and parenteral drug delivery systems. CAPMUL excipients are recognized as the ideal starting point when formulating BCS Class II & IV (poorly water soluble) and BCS Class III & IV (poorly permeable) molecules. Lipid-based drug delivery systems may be formulated as liquid or semi-solid formulations for oral dosage forms, as well as creams and ointments for topical and transdermal applications.
CAPMUL may be used as a majority component in solubilization/emulsification formulations. Or whenever necessary, CAPMUL-based formulations may be customized with the inclusion of CAPTEX® medium-chain triglycerides and/or ACCONON® non-ionic surfactants, added for enhanced bioavailability.
ABITEC’s INJECTATM parenteral-grade lipid excipients to enable improved solubilization and permeation for injectable APIs. The INJECTA-grade portfolio of products include: CAPTEX medium-chain tri-glycerides, CAPMUL mono-and di-glycerides of glycol esters, and ACCONON non-ionic surfactants, fully analyzed and packaged for parenteral application.
ABITEC manufactures high-quality lipid excipients for drug delivery applications in accordance with strict cGMP and applicable IPEC (International Pharmaceutical Excipient Council) guidelines in ISO-certified facilities. ABITEC’s customer-preferred portfolio of pharmaceutical excipients are monograph compliant, supported by drug master files (DMFs), and have precedence of use. For more information about all of ABITEC’s invaluable solutions please contact us directly or visit our website at www.abiteccorp.com.
Dosage Forms Include: Oral, Injectable, Topical & Transdermal, Suppositories, Ophthalmic, and Inhaled
Application Include: Solubilization, Emulsification, Lubricating Dry Binder, Permeation Enhancement, Encapsulation, Controlled Release, and Self-Emulsifying Drug Delivery Systems
Future Growth is Our Priority
ABITEC is continuing to look at ways they can expand their capabilities to better serve the pharmaceutical market sectors. The acquisition of Larodan is already bringing new technologies and opportunities to the forefront, but in the coming year there will be even more exciting advancements to share!
To Request a Sample – visit https://samples.abiteccorp.com/
Social Media Links:
Twitter – https://twitter.com/abiteccorp
Posted Date: 12/1/2021
This record has been viewed 1161 times.